CorMedix - About the company
CorMedix is a public company based in Bridgewater (United States), founded in 2006. It operates as a Commercial stage biopharma company with focus on cardiac, renal and infectious diseases. CorMedix has raised $2.62M in funding.
Company Details
CorMedix Inc. is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. Its first product Neutrolin provides a preventative solution, which decreases the triple threat of infection, thrombosis and biofilm formation thereby keeping catheters operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation for oncology, hemodialysis, and intensive care patients. Neutrolin is CE approved in europe and company plans to expand distribution in USA, middle east, south america and africa
- Website
- cormedix.com
Key Metrics
Founded Year
2006
Location
Bridgewater, United States
Stage
Public
Total Funding
$2.62M in 3 rounds
Latest Funding Round
Investors
Annual Revenue
$100M - $500M as on Dec 31, 2025
Employee Count
185 as on Sep 30, 2026
Exit Details
Public
Legal entities associated with CorMedix
CorMedix is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
CORMEDIX INC. CIN: 1410098 , United States, Active | Jul 27, 2006 | $100M - $500M (As on Dec 31, 2025) | 40 (As on Mar 31, 2023) | - |
CorMedix's IPO details
CorMedix got listed on Mar 25, 2010.
Click here to take a look at CorMedix's IPO in detail
Sign up to download CorMedix's company profile
CorMedix's funding and investors
CorMedix has raised a total funding of $2.62M over 3 rounds. Its first funding round was on Nov 12, 2009. Its latest funding round was a Grant (prize money) round on Aug 15, 2017 for $*****. 1 investor participated in its latest round. CorMedix has 2 institutional investors.
Here is the list of recent funding rounds of CorMedix:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 15, 2017 | 3530945 | Grant (prize money) | 6549498 | 7155689 | 2702210 | 8618687 |
Oct 20, 2013 | 2089090 | Post IPO | 8488124 | 3071100 | 7261579 | 8624777 |
Nov 12, 2009 | 3599414 | Seed | 6632701 | 5112904 | 4444978 | 6954286 |
View details of CorMedix's funding rounds and investors
CorMedix's founders and board of directors
Founder? Claim ProfileCorMedix's employee count trend
CorMedix has 185 employees as of Sep 26. Here is CorMedix's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
CorMedix's Investments and acquisitions
CorMedix has made 1 investment in Talphera and acquired Melinta Therapeutics and Melinta Therapeutics.Here is the list of these investments and acquisitions:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Sep 08, 2025 | Investments | 2005 | San Mateo (United States) | |
Aug 07, 2025 | Acquisition | 2000 | Morristown (United States) | |
2020 | Acquisition | 2000 | Morristown (United States) |
Reports related to CorMedix
Here is the latest report on CorMedix's sector:
News related to CorMedix
Media has covered CorMedix for a total of 14 events in the last 1 year, 5 of them have been about company updates and 1 about people movement.
•
CorMedix: Durable Commercial Base, But 2027 Is The Real Test (NASDAQ:CRMD)Seeking Alpha•Aug 18, 2026•CorMedix
•
CorMedix (CRMD) Q2 2026 Earnings Call: Revenue Hits $101.9M, EBITDA Guidance RaisedNews Break•Aug 14, 2026•CorMedix
•
CorMedix Inc. (CRMD) revenue jumps as Melinta deal boosts Q2 2026 profitStocktitan•Aug 13, 2026•CorMedix
•
CorMedix Therapeutics Wins Patent Litigation Against Nexus Pharmaceuticals for Minocin®GlobeNewswire•Jun 08, 2026•CorMedix
•
CorMedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire•May 14, 2026•CorMedix
•
•
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for Prophylaxis of InvasiGlobeNewswire•Apr 27, 2026•CorMedix
•
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire•Mar 05, 2026•CorMedix
•
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026GlobeNewswire•Jan 29, 2026•CorMedix
•
Are you a Founder ?
FAQs about CorMedix
Explore our recently published companies
- Lacy And Par - Tukwila based, 1984 founded, Unfunded company
- Moeheat - Santa Clarita based, 2008 founded, Public company
- Z-axis Prints - Spokane based, 2010 founded, Unfunded company
- Zen Creative Group - Portland based, 1995 founded, Unfunded company
- Rjo Ventures - North Miami Beach based, 2011 founded, Unfunded company
- Roberts Design - Las Vegas based, 2014 founded, Unfunded company